An Adelaide GP has criticised access to medicinal cannabis in Australia as “unworkable”, saying regulations surrounding medicinal cannabis sits in contrast to the way opioids are dispensed to patients.
The doctor said the Special Access Scheme (SAS) laid out by the Therapeutic Goods Administration (TGA) was difficult for doctors to navigate with requirements needing to be met across both state and federal levels.
She said that peak Australian bodies such as Australian Medical Association (AMA) and the Royal Australian College of General Practitioners (RACGP) have adopted conservative positions and provided little guidance or information on how medicinal cannabis could be of benefit to patients or the SAS process.
Read the article here.
In conjunction with the HMRI and lead biomedical scientist Dr Matt Dun, we’re investigating the anticancer properties of our plant varieties. Dr Matt Dun shares his initial thoughts on the joint research project.
We’re thrilled to announce we have received our export licence from the Drug Control Section of the ODC (Office of Drug Control). We’re firmly on course to continue to lead the way and be the first medicinal cannabis company in Australia to export cannabis flower to the EU since export was legalised in 2018.
We are focused on research and development, partnering with leading scientists and medical institutions to develop cannabinoid medicines that offer safe and effective therapeutic benefits.LEARN ABOUT ANTG HERE >